Managing Alpha1-antitrypsin* deficiency can feel overwhelming until you have—

a clear path forward.

GLASSIA® [Alpha1‑Proteinase Inhibitor (Human)] is used to treat adults with lung disease (emphysema) because of severe Alpha1‑antitrypsin (AAT) deficiency. GLASSIA is not meant to be used as a therapy in individuals with lung disease other than severe Alpha1‑PI deficiency.

Effects of GLASSIA on worsening lung function and emphysema progression have not been proven in clinical trials. Long-term effects of Alpha1 replacement and maintenance therapy have not been studied.

*Alpha1‑antitrypsin is sometimes referred to as just Alpha1

Want to get updates on Alpha1 deficiency and GLASSIA?

Sign Up

Get a Clear


About Your Condition

The more you know about Alpha1 deficiency and lung disease (emphysema), the more you’ll understand how important treatment can be.

Lungs icon

Alpha1 is a protein that helps protect the lungs

Alpha1 circulates in your bloodstream and helps protect the elastic structures of your lungs from an enzyme that can attack normal body tissue. Without enough functional Alpha1, lung damage can develop, usually in people between 20 and 50 years of age.

Liquid icon

Emphysema can be caused by a severe Alpha1 deficiency

A severe Alpha1 deficiency can lead to emphysema—a lung condition that causes shortness of breath—with symptoms that can worsen over time.

Branch icon

Alpha1 deficiency can run in families

Alpha1 deficiency is caused by a genetic mutation that occurs in about 1 of every 3,000 to 5,000 people in the U.S. It’s also the most common genetic cause of emphysema.

Know this:

you’re not alone.

1  In Every
3,000 – 5,000

Americans lives with Alpha1 deficiency.

Talk to your doctor if you have questions about family testing, living with Alpha1 deficiency, or augmentation therapy.

Start Your


With Clarity

Know how GLASSIA works. Know what treatment experience works best for you.

Chart icon


The Alpha1 protein protects the lung tissue by blocking certain enzyme-caused damage. Such damage can lead to severe lung disease, such as emphysema.

Alpha1 augmentation is chronic maintenance therapy. So, GLASSIA is typically given once every week to increase levels of Alpha1 in your blood and lungs.

Drip icon

GLASSIA is ready to infuse

GLASSIA is an intravenous (into a vein) infusion that generally takes about 15 minutes at the recommended dose and maximum infusion rate.

Bell icon

GLASSIA puts you in control of your infusion experience

GLASSIA’s flexibility of administration lets you decide where you want to infuse. Talk to your healthcare provider about which administration option works best for you:

  • In the clinic by a healthcare provider
  • At an outpatient infusion center
  • At home by a healthcare provider
  • At home through self-infusion or by a caregiver—after appropriate training

If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.

The first FDA‑approved

Liquid Alpha1 augmentation therapy, GLASSIA has been prescribed by pulmonologists for 10 years running.

Talk to your doctor about GLASSIA.

Keep Moving Forward With


Know that OnePath is here for you after you and your physician choose your treatment path.

Hand right icon

Personalized product support from OnePath

After you enroll in OnePath, you will receive a dedicated Patient Support Manager who will be your main point of contact throughout your treatment journey. Your Patient Support Manager will work with you one-on-one to make sure you have access to your prescribed Takeda medication.

He or she will help you navigate many different aspects of your therapy, from insurance and financial options to training and prescription fulfillment.

Folder icon

OnePath helps you:

  • Navigate the health insurance process
  • Enroll in the OnePath Co-Pay Assistance Program (if eligible) or discuss financial assistance options
  • Coordinate medication delivery with your specialty pharmacy
  • Receive free self-administration training with a nurse (if applicable)
  • Learn about additional support, education, and community resources
Card icon


The OnePath Co-Pay Assistance Program helps cover certain out-of-pocket treatment costs for eligible, commercially insured patients who are enrolled in OnePath.

The following are covered up to the program maximum and may be paid directly to the provider:

  • 100% coverage of eligible out-of-pocket costs, which may include deductibles, co-pays, and co-insurance§
  • Out-of-pocket cost of eligible infusion charges where applicable by law

At a minimum, to be eligible for the program, a patient must:

  • Be enrolled in OnePath
  • Have commercial insurance
  • Other eligibility requirements apply. For more information, please contact a OnePath Patient Support Manager at 1‑866‑888‑0660.

OnePath is open to all patients taking GLASSIA for its indicated use and who complete the GLASSIA OnePath Start Form, which provides OnePath with your consent to provide product support.

§Subject to program terms, limits, and conditions

IMPORTANT NOTICE: The OnePath Copay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.


Call OnePath at 1-866-888-0660. OnePath is available Monday through Friday, 8:30 AM to 8:00 PM ET. Keep the OnePath number (1-866-888-0660) in your phone so you don’t confuse us with spam calls. If you miss a call from us, please call us back. If you give us permission, we can leave a voicemail saying why we called.



in touch

Sign up, and we’ll make sure you get the latest information about Alpha1 deficiency and GLASSIA.

Are you a:


What is GLASSIA?

GLASSIA is a medicine containing human Alpha₁-Proteinase Inhibitor (Alpha₁-PI) also known as alpha₁-antitrypsin (AAT) and is used to treat adults with lung disease (emphysema) because of severe Alpha1 antitrypsin (AAT) deficiency. GLASSIA is not meant to be used as a therapy in individuals with lung disease other than severe Alpha₁-PI deficiency.

Important Safety Information

What is the most important information I need to know about GLASSIA?

  • GLASSIA can cause severe allergic reactions including hives, swelling in the mouth or throat, itching, tightness in the chest, trouble breathing, wheezing, faintness or low blood pressure
  • If you will be taking GLASSIA outside a healthcare setting, ask your healthcare provider (HCP) about an epinephrine pen and/or other supportive care for certain severe allergic reactions.

Who should not use GLASSIA?

Do not use GLASSIA if you:

  • Have immunoglobulin A (IgA) deficiency with antibodies to IgA
  • Have a severe allergic reaction to human Alpha1-PI products.

What are the possible or reasonably likely side effects of GLASSIA?

If any of the following problems occur contact your healthcare provider (HCP) or call emergency services right away:
  • Worsening or flare-up of your chronic obstructive pulmonary disease (COPD)
  • Hives, swelling in the mouth or throat, itching, chest tightness, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.

The most common side effects that may occur are headache and upper respiratory tract infections

Other possible side effects of GLASSIA include:

  • Cough
  • Sinus infection
  • Chest discomfort
  • Dizziness
  • Increased liver enzymes
  • Shortness of breath
  • Nausea
  • Fatigue

These are not all the possible side effects. Tell your HCP about any side effect that bothers you or that does not go away.

For additional safety information, click for Information For Patients including Instructions For Use and discuss with your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1‑800‑FDA‑1088.